CN107298705A - 半滑舌鳎mch2蛋白及其体外表达制备方法和应用 - Google Patents
半滑舌鳎mch2蛋白及其体外表达制备方法和应用 Download PDFInfo
- Publication number
- CN107298705A CN107298705A CN201710649072.2A CN201710649072A CN107298705A CN 107298705 A CN107298705 A CN 107298705A CN 201710649072 A CN201710649072 A CN 201710649072A CN 107298705 A CN107298705 A CN 107298705A
- Authority
- CN
- China
- Prior art keywords
- mch2
- cynoglossus semilaevis
- albumen
- protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001014350 Cynoglossus semilaevis Species 0.000 title claims abstract description 54
- 230000014509 gene expression Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 102100027373 Melanin-concentrating hormone receptor 2 Human genes 0.000 title claims abstract 14
- 101710089759 Melanin-concentrating hormone receptor 2 Proteins 0.000 title claims abstract 14
- 238000000338 in vitro Methods 0.000 title abstract 3
- 238000003259 recombinant expression Methods 0.000 claims abstract description 22
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000013604 expression vector Substances 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 238000001742 protein purification Methods 0.000 claims abstract description 6
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical group CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000000746 purification Methods 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 208000009786 Anophthalmos Diseases 0.000 description 13
- 241000251468 Actinopterygii Species 0.000 description 10
- 208000003351 Melanosis Diseases 0.000 description 8
- 241000269981 Bothidae Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 101150104680 MCH1 gene Proteins 0.000 description 6
- 101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000001817 pituitary effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000694873 Paralichthyidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- KUYKVGODHGHFDI-ACZMJKKPSA-N Asn-Gln-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O KUYKVGODHGHFDI-ACZMJKKPSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- YTXCCDCOHIYQFC-GUBZILKMSA-N Asp-Met-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTXCCDCOHIYQFC-GUBZILKMSA-N 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- CUYLIWAAAYJKJH-RYUDHWBXSA-N Gly-Glu-Tyr Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUYLIWAAAYJKJH-RYUDHWBXSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- CNNQBZRGQATKNY-DCAQKATOSA-N Leu-Arg-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N CNNQBZRGQATKNY-DCAQKATOSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- SQUTUWHAAWJYES-GUBZILKMSA-N Met-Asp-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SQUTUWHAAWJYES-GUBZILKMSA-N 0.000 description 1
- GETCJHFFECHWHI-QXEWZRGKSA-N Met-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCSC)N GETCJHFFECHWHI-QXEWZRGKSA-N 0.000 description 1
- UDOYVQQKQHZYMB-DCAQKATOSA-N Met-Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDOYVQQKQHZYMB-DCAQKATOSA-N 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- AHXPYZRZRMQOAU-QXEWZRGKSA-N Pro-Asn-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1)C(O)=O AHXPYZRZRMQOAU-QXEWZRGKSA-N 0.000 description 1
- CKXMGSJPDQXBPG-JYJNAYRXSA-N Pro-Cys-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O CKXMGSJPDQXBPG-JYJNAYRXSA-N 0.000 description 1
- 241000157468 Reinhardtius hippoglossoides Species 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- 241001417980 Soleidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- JXCOEPXCBVCTRD-JYJNAYRXSA-N Val-Tyr-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JXCOEPXCBVCTRD-JYJNAYRXSA-N 0.000 description 1
- 241000410737 Verasper moseri Species 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 101150024647 mch gene Proteins 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种半滑舌鳎MCH2蛋白及其体外表达制备方法和应用,所述蛋白的核苷酸序列为SEQ ID NO:1;所述蛋白氨基酸的序列为SEQ ID NO:2。所述半滑舌鳎MCH2蛋白的体外表达制备方法,它包括重组表达载体构建、重组表达载体诱导表达和重组蛋白纯化;所述重组表达载体构建为将原核表达载体PET32a与目的核苷酸片段进行重组,构成可表达氨基酸序列为SEQ ID NO:2的半滑舌鳎黑色素富集素2(MCH2)多肽的重组表达载体。所述重组表达载体,实现了半滑舌鳎MCH2多肽在原核生物体内的规模化、低成本生产,通过纯化可获得用于注射用或者饲料添加的生物功能制品。
Description
技术领域
本发明属于分子生物学领域,具体涉及一种半滑舌鳎MCH2蛋白及其体外表达制备方法和应用。
背景技术
鲆鲽鱼类是指身体侧扁、双眼同位于身体一侧、体两侧不对称着色(有眼侧着色、无眼侧白色)、营底栖生活的硬骨鱼类,一般统指鲽形目鱼类。我国是世界鲆鲽鱼类养殖大国,2012年鲆鲽类养殖产量达到14.04万吨,占我国海水鱼类养殖总产量的10.73%(中国渔业统计年鉴,2016)。目前,我国养殖鲆鲽鱼类的主要品种包括大菱鲆、牙鲆、半滑舌鳎等,养殖过程中养殖鱼特别是半滑舌鳎、牙鲆等普遍存在无眼侧体色变黑的现象,主要表现为无眼侧皮肤表面部分(20%-50%)覆盖斑状黑色素(主要出现在腹面的近尾端和体中部)或腹面全部被黑色素覆盖,而且这种无眼侧体色变黑的发生率高达60%-90%。这种无眼侧体色变黑的养殖半滑舌鳎商品鱼的市场价格比无眼侧体色为白色的正常鱼低15%-20%,成为制约半滑舌鳎等鲆鲽鱼类养殖产业提质增效的瓶颈之一。另外,无眼侧体色变黑的苗种也不适用于增殖放流。
黑色素富集素(MCH)是下丘脑神经元分泌的一种小分子肽,最早在鱼类中发现,是MCH基因编码的产物,其合成后分泌到垂体神经叶,最终进入血液循环系统扮演神经递质或神经调质的角色,促进黑色素细胞内黑色素颗粒凝集而使得鱼体色变浅。研究已经证明,MCH同另一种与其生理拮抗的小分子神经肽--黑素细胞刺激素(MSH)一起通过内分泌或旁分泌途径参与鱼类体色的调控。研究已经证实,MCH在抑制鲆鲽鱼类无眼侧体色变黑方面具有重要的生理调控作用,如利用外源的MCH肽可显著抑制条斑星鲽体色黑化(Takahashi etal,Gen.Comp.Endocrinol.,2004,135:159–165),表明在养殖生产过程中可利用MCH产物来调控鲆鲽鱼类无眼侧体色黑化,如能规模化生产并应用在养殖过程中,其带来的养殖效益提升前景广阔。MCH有两种分子形式MCH1和MCH2(Mizusawa et al,Gen.Comp.Endocrinol.,2015,214:140–148),他们的产物蛋白具有类似的体色黑化抑制调控功能。鱼类MCH还具有明显的促生长调控作用,是饲料添加剂的优良来源。然而,目前无论是MCH1还是MCH2蛋白的获得尚依赖于人工合成,产量低、成本高,且仅用于试验用途,尚无法进行批量化生产应用于养殖生产。
发明内容
为了解决上述技术问题,本发明提供一种半滑舌鳎MCH2蛋白及其体外表达制备和应用方法,利用获得的半滑舌鳎MCH2基因的成熟肽序列,重组进原核表达载体建立MCH2重组表达载体,并通过生产条件优化在原核生物中进行大量表达,从而获得大批量具有生物活性的体外制备的重组半滑舌鳎MCH2蛋白,可在半滑舌鳎养殖生产中应用,有效控制无眼侧体色黑化的发生,显著提升养殖效益。
本发明通过以下技术方案实现:
一种半滑舌鳎MCH2蛋白,所述半滑舌鳎MCH2蛋白的核苷酸序列为SEQ IDNO:1;
一种半滑舌鳎MCH2蛋白,所述半滑舌鳎MCH2蛋白的氨基酸序列为SEQ IDNO:2;
本发明还提供一种半滑舌鳎MCH2蛋白的体外表达制备方法,它包括重组表达载体构建、重组表达载体诱导表达和重组蛋白纯化。
所述的重组表达载体构建,其特征在于将原核表达载体PET32a与目的核苷酸片段进行重组,构成可表达氨基酸序列为SEQ IDNO:2的半滑舌鳎黑色素富集素2(MCH2)多肽的重组表达载体。
进一步,所述的MCH2成熟肽的目的核苷酸片段的序列为SEQ IDNO:1。
所述的重组表达载体诱导表达,将重组表达载体导入表达宿主菌BL21(DE3)pLysS,并利用诱导剂诱导重组表达载体在宿主菌中大量表达。
进一步,所述的诱导剂为异丙基硫代半乳糖苷(IPTG)。
进一步,诱导条件为:温度为27℃,IPTG浓度为0.2mmol/L,诱导时间为6h。
所述的重组蛋白纯化,其特征在于将表达了目的蛋白的BL21(DE3)pLysS菌株收集离心、破碎后以Ni2+-NTA亲和层析柱分离并纯化。
本发明还提供一种所述体外制备的MCH2蛋白在饲料中的应用。
本发明提供一种包含有所述体外制备的MCH2蛋白饲料添加剂。
本发明与现有技术的对比的有益效果:
本发明筛选了一种适宜半滑舌鳎MCH2体外表达的原核载体,获得了可用于量化生产的重组表达载体,实现了半滑舌鳎MCH2多肽在原核生物体内的规模化、低成本生产,通过纯化可获得用于注射用或者饲料添加的生物功能制品。本发明获得的半滑舌鳎MCH2蛋白可以水剂或者专用饲料添加剂的形式,广泛应用于半滑舌鳎养殖体色调控及摄食生长调控研究,为养殖半滑舌鳎等鲆鲽鱼类无眼侧体色黑化问题提供了解决方案,以科技推动养殖技术进步和提质增收。
附图说明
图1半滑舌鳎MCH2重组蛋白的表达与纯化
M:蛋白Marker;1:pET32a空载2:27℃条件下0.2mmol/LIPTG诱导6h的重组MCH2蛋白表达菌;3-4:Ni2+-NTA纯化柱纯化后蛋白液(箭头示32.1kD重组蛋白)
图2半滑舌鳎MCH2重组蛋白对离体孵育的垂体基因表达的影响
注:MCH1(A1),MCH2(A2),POMC-a(B1),POMC-b(B2),MCHR1(C1),MCH1(C2),PACAP(D1),MITF(D2)mRNA表达水平变化,不同字母代表显著性差异(P<0.05)
具体实施方式
下面通过实施例结合附图来对本发明的技术方案做进一步解释,但本发明的保护范围不受实施例任何形式上的限制。
1、半滑舌鳎MCH2成熟肽扩增
取样半滑舌鳎成鱼垂体组织,提取总RNA,反转录为cDNA保存。根据半滑舌鳎MCH2成熟肽的cNDA序列(SEQ IDNO:1),设计一对特异性引物克隆成熟肽序列,在引物的两端分别引入限制性内切酶位点BamH I和Hind III,在MCH2-R引物中加入强终止密码子TAA,用于扩增半滑舌鳎MCH2成熟肽序列,引物序列如下:
MCH2-F:5-′ATAGGATCCAGCCACCTAGTGGTCG-3′
MCH2-R:5′-ATAAAGCTTTTATCAGTTGGAGGTTCCCC-3′;
PCR体系为20μl,扩增条件为:94℃5min变性,(94℃30s、58℃30s、72℃50s)34个循环,最后72℃延伸10min。将得到的成熟肽片段连接到pEASY-T1 Simple载体上,转化DH5α感受态细胞,平板培养后挑选阳性克隆测序验证序列是否正确。
2、重组表达载体构建
提取MCH2/pEASY-T1质粒,以限制性内切酶BamH I和Hind III将MCH2/pEASY-T1质粒和表达载体pET-32a双酶切,使用T4连接酶将目的片段连接到pET-32a上,得到用于表达序列为SEQ ID NO:2的半滑舌鳎MCH2的重组表达载体,再次转化至大肠杆菌DH5α中,菌液PCR验证后并测序。
3、重组表达载体诱诱导表达与鉴定
将验证正确的重组表达载体转化到表达菌株BL21(DE3)pLysS中,挑取阳性单克隆接种于含氨苄青霉素(100μg/mL)的LB培养基中,37℃振荡培养过夜,并按1:100扩大培养至OD600值为0.6-0.7后,加入IPTG(1mmol/L)继续诱导培养。分别设置不同的诱导培养时间、培养温度和IPTG浓度,诱导MCH2在表达菌株中的表达,获得最佳的表达条件为温度为27℃,IPTG浓度为0.2mmol/L,诱导时间为6h,此时MCH2蛋白的表达率可达55%。利用Western-blotting方法验证获得目的蛋白条带的特异性,如图1所示。
4、重组蛋白纯化
重组MCH2菌种接种到500ml LB培养基中(含有100μg/ml氨苄霉素),27℃条件下IPTG(0.2mmol/L)诱导重组菌6h后,4℃、12000r/min离心10min收集菌体,每克菌体加入结合缓冲液(20mmol/L Na3PO4,0.5mol/L NaCl,20mmol/L咪唑)15ml重悬菌体。在–80℃条件下反复冻融菌液3次,冰浴进行超声破碎(800W),5s超声,5s间隔,破碎30min左右。破碎后用4℃、12000r/min离心10min收集上清液,先后用0.8μm和0.45μm微孔滤膜过滤,然后经Ni2+-NTA亲和层析柱分离、纯化目的蛋白,得到的纯化MCH1重组蛋白相对分子质量约为32.1kD,符合预期计算值,获得的重组MCH2蛋白浓度为900μg/mL。
5、半滑舌鳎MCH2蛋白生物活性测定
取半滑舌鳎成鱼的垂体组织,以L15培养基清洗后置于含10%小牛血清的L15培养液中培养6小时,之后用含有不同浓度MCH2重组蛋白(0nmol/L、1nmol/L、10nmol/L、100nmol/L和1000nmol/L)的无小牛血清的L15培养液中孵育,在CO2细胞培养箱中25℃培养24h,培养结束后收集组织孵育液和垂体组织。
获得的半滑舌鳎MCH2重组蛋白在100nmol/L时可显著提升离体孵育的垂体组织孵育液中MCH肽含量,并在1000nmol/L达到峰值,此时孵育液中MCH肽含量显著增加并达到峰值。同时,获得的半滑舌鳎MCH2重组蛋白可促进离体孵育的垂体组织中MCH1 mRNA表达水平在10nmol/L显著升高并达到峰值,但在100nmol/L之后显著降低;MCH2 mRNA表达水平在1000nmol/L时显著升高达到峰值;POMC-a mRNA表达水平在100nmol/L显著升高,POMC-bmRNA表达水平在100nmol/L开始显著下降。表明获得的半滑舌鳎MCH2重组蛋白具有较理想的生物活性,如图2所示。
6、半滑舌鳎MCH2重组蛋白的应用
本发明提供的半滑舌鳎MCH2蛋白体外表达制备方法可成功实现半滑舌鳎MCH2成熟肽在大肠杆菌中的高效表达。将成功表达MCH2成熟肽的菌株经分离纯化等步骤后,可获得MCH2重组蛋白,以去离子水保存成水剂,可用于科学实验研究。例如,按照5μg/kg的MCH2重组蛋白剂量,对无眼侧皮肤发生严重黑化(90%)的半滑舌鳎进行背部肌肉皮下注射,在一周内可有效减弱无眼侧黑化症状。如对获得的重组蛋白进行微滤、超滤、喷雾干燥、冻干等处理后可获得粉剂产品,可用于饲料添加剂使用。例如,按照0.1%的添加比例将MCH2重组蛋白添加进半滑舌鳎饲料重,可显著促进半滑舌鳎摄食,同时还可有效控制无眼侧体色黑化的发生和发育进程。
SEQUENCE LISTING
<110> 中国水产科学研究院黄海水产研究所
<120> 半滑舌鳎MCH2蛋白及其的体外表达制备方法和应用
<130> 无
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 387
<212> DNA
<213> Cynoglossus semilaevis Gunther
<400> 1
agccacctag tggtcgtagc catgcccgag accaagggag aagatgccat gatggagcag 60
gacagcctgg gttcgttact gggggaggag agcctgacgg accgagccat gcttccatca 120
gcgtatgcta acggcctgat gttgaacaac tacagagcag acgacggaaa ccctaacgtt 180
ctaattttct cggacatgcg gcaaaaagga cagggcattc gtgggctgag tccaggtttt 240
acccgaagcc ttcctcaaat cacagaccga aagatgaacc agtccccggg cgaatatagt 300
ctgaaaatgg atcgacgaaa cactgaactt gacatgctgc gctgcatgat aggcagagtt 360
taccgaccct gctggggaac ctccaac 387
<210> 2
<211> 129
<212> PRT
<213> Cynoglossus semilaevis Gunther
<400> 2
Ser His Leu Val Val Val Ala Met Pro Glu Thr Lys Gly Glu Asp Ala
1 5 10 15
Met Met Glu Gln Asp Ser Leu Gly Ser Leu Leu Gly Glu Glu Ser Leu
20 25 30
Thr Asp Arg Ala Met Leu Pro Ser Ala Tyr Ala Asn Gly Leu Met Leu
35 40 45
Asn Asn Tyr Arg Ala Asp Asp Gly Asn Pro Asn Val Leu Ile Phe Ser
50 55 60
Asp Met Arg Gln Lys Gly Gln Gly Ile Arg Gly Leu Ser Pro Gly Phe
65 70 75 80
Thr Arg Ser Leu Pro Gln Ile Thr Asp Arg Lys Met Asn Gln Ser Pro
85 90 95
Gly Glu Tyr Ser Leu Lys Met Asp Arg Arg Asn Thr Glu Leu Asp Met
100 105 110
Leu Arg Cys Met Ile Gly Arg Val Tyr Arg Pro Cys Trp Gly Thr Ser
115 120 125
Asn
<210> 3
<211> 24
<212> DNA
<213> Artificial
<220>
<223> MCH2-F
<400> 3
ataggatcca gccacctagt ggtc 24
<210> 4
<211> 28
<212> DNA
<213> Artificial
<220>
<223> MCH2-R
<400> 4
ataaagcttt tatcagttgg aggttccc 28
Claims (7)
1.一种半滑舌鳎MCH2蛋白,其特征在于所述半滑舌鳎MCH2蛋白的核苷酸序列为SEQIDNO:1。
2.权利要求1所述的一种半滑舌鳎MCH2蛋白,其特征在于所述半滑舌鳎MCH2蛋白的氨基酸序列为SEQ IDNO:2。
3.权利要求1所述一种半滑舌鳎MCH2蛋白的体外表达制备方法,其特征在于它包括重组表达载体构建、重组表达载体诱导表达和重组蛋白纯化;
所述的重组表达载体构建,将原核表达载体PET32a与目的核苷酸片段SEQ IDNO:1进行重组,构成可表达氨基酸序列为SEQ IDNO:2的半滑舌鳎黑色素富集素2多肽的重组表达载体;
所述的重组表达载体诱导表达,将重组表达载体导入表达宿主菌BL21(DE3)pLysS,并利用诱导剂诱导重组表达载体在宿主菌中大量表达;
所述的重组蛋白纯化,将表达了目的蛋白的BL21(DE3)pLysS菌株收集离心、破碎后以Ni2+-NTA亲和层析柱分离并纯化。
4.权利要求3所述的一种半滑舌鳎MCH2蛋白的体外表达制备方法,其特征在于所述的诱导剂为异丙基硫代半乳糖苷。
5.权利要求3所述的一种半滑舌鳎MCH2蛋白的体外表达制备方法,其特征在于,诱导条件为:温度为27℃,IPTG浓度为0.2mmol/L,诱导时间为6h。
6.权利要求3所述的一种所述体外制备的MCH2蛋白在饲料中的应用。
7.一种包含有权利要求3所述体外制备的MCH2蛋白饲料添加剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710649072.2A CN107298705A (zh) | 2017-08-01 | 2017-08-01 | 半滑舌鳎mch2蛋白及其体外表达制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710649072.2A CN107298705A (zh) | 2017-08-01 | 2017-08-01 | 半滑舌鳎mch2蛋白及其体外表达制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107298705A true CN107298705A (zh) | 2017-10-27 |
Family
ID=60133310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710649072.2A Pending CN107298705A (zh) | 2017-08-01 | 2017-08-01 | 半滑舌鳎mch2蛋白及其体外表达制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107298705A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089038A2 (en) * | 2004-03-23 | 2005-09-29 | Universidade Federal Do Rio De Janeiro-Ufrj | Method for cloning, expression and purification of the amyloid polypeptide from human pancreatic islets |
CN104593402A (zh) * | 2015-01-21 | 2015-05-06 | 吉林农业大学 | 运用大肠杆菌作为生物反应器生产重组的抗肿瘤19肽的方法 |
-
2017
- 2017-08-01 CN CN201710649072.2A patent/CN107298705A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089038A2 (en) * | 2004-03-23 | 2005-09-29 | Universidade Federal Do Rio De Janeiro-Ufrj | Method for cloning, expression and purification of the amyloid polypeptide from human pancreatic islets |
CN104593402A (zh) * | 2015-01-21 | 2015-05-06 | 吉林农业大学 | 运用大肠杆菌作为生物反应器生产重组的抗肿瘤19肽的方法 |
Non-Patent Citations (1)
Title |
---|
徐永江等: "半滑舌鳎(Cynoglossus semilaevis)黑色素富集激素基因的克隆和表达", 《渔业科学进展》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017206326A1 (zh) | 一种重组人源胶原蛋白及其编码基因和制备方法 | |
CN111334512A (zh) | 含羟脯氨酸与羟赖氨酸的重组类人胶原蛋白及其生产方法 | |
CN102399284B (zh) | 狐狸生长激素释放激素cDNA及其应用 | |
CN115558612A (zh) | 重组全长ⅲ型人源化胶原蛋白酵母工程菌株及构建方法 | |
CN102399283A (zh) | 水貂生长激素释放激素cDNA及其应用 | |
WO2023221787A1 (zh) | 重组i型胶原蛋白毕赤酵母工程菌及其构建方法与应用 | |
CN108840947A (zh) | 牛白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素 | |
CN112239760B (zh) | 高效表达重组hGH的重组工程菌及构建方法和应用 | |
CN117903319A (zh) | 一种人乳铁蛋白肽三聚体融合蛋白及其制备方法和应用 | |
CN107287176A (zh) | 一种耐高温中性植酸酶Physh-A及其基因和应用 | |
CN109997970B (zh) | 一类酶活和耐热性提高的酸性木聚糖酶突变体及其编码基因和应用 | |
CN103917655A (zh) | 核心蛋白聚糖组合物及其用途 | |
CN104988170B (zh) | 一种融合抗菌肽及其制备方法和应用 | |
CN101824435A (zh) | 一种罗非鱼神经肽y重组蛋白的表达系统 | |
CN107298705A (zh) | 半滑舌鳎mch2蛋白及其体外表达制备方法和应用 | |
CN108822220A (zh) | 羊白蛋白-干扰素τ-白介素2融合蛋白、制备方法及其编码基因、一种羊长效干扰素 | |
CN110257395B (zh) | 草鱼adiponectin A基因、编码蛋白及其应用 | |
CN109608535B (zh) | 一种优化的鸡α干扰素肽链及其重组表达工程菌株 | |
CN101736029A (zh) | 一种利用植物油体蛋白表达系统生产人胰岛素样生长因子-i的方法 | |
Yan et al. | Overexpression of a small medicinal peptide from ginseng in the yeast Pichia pastoris | |
CN103709242A (zh) | 一种基于红鳍东方鲀FoxO1基因的重组蛋白、制备方法及应用 | |
CN108752459A (zh) | 半滑舌鳎igf-i蛋白及其体外表达制备方法与应用 | |
CN109096383B (zh) | 一种鱼源抗菌肽parasin I突变体及其应用 | |
CN110317821A (zh) | 一种融合蛋白thg及其应用 | |
CN110607306A (zh) | 一种重组猪表皮生长因子的表达方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171027 |